Differentially expressed genes in human peripheral blood as potential markers for statin response

[1]  H. Jing,et al.  Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor γ. , 2010, European journal of pharmacology.

[2]  M. Barančík,et al.  Omega-3 fatty acids and atorvastatin suppress ventricular fibrillation inducibility in hypertriglyceridemic rat hearts: implication of intracellular coupling protein, connexin-43. , 2010, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[3]  A. Quyyumi,et al.  FOS expression in blood as a LDL-independent marker of statin treatment. , 2010, Atherosclerosis.

[4]  Jie Du,et al.  Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a “Western-style diet” by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels , 2010, Acta Pharmacologica Sinica.

[5]  J. Piek,et al.  Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. , 2009, Journal of molecular and cellular cardiology.

[6]  A. Bredberg,et al.  Use of atorvastatin as an anti‐inflammatory treatment in Crohn's disease , 2008, British journal of pharmacology.

[7]  E. Ros,et al.  Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment. , 2008, Pharmacogenomics.

[8]  M. Hirata,et al.  Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[9]  Seppo Ylä-Herttuala,et al.  Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. , 2008, Cardiovascular research.

[10]  M. Wolzt,et al.  In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model , 2008, Pharmacogenetics and genomics.

[11]  C. Jun,et al.  Transcriptional regulation of IL‐8 by iron chelator in human epithelial cells is independent from NF‐κB but involves ERK1/2‐ and p38 kinase‐dependent activation of AP‐1 , 2007, Journal of cellular biochemistry.

[12]  M. Chopp,et al.  The PI3K/Akt Pathway Mediates the Neuroprotective Effect of Atorvastatin in Extending Thrombolytic Therapy After Embolic Stroke in the Rat , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[13]  V. Canzonieri,et al.  Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells , 2007, Clinical and experimental immunology.

[14]  J. Voltarelli,et al.  Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). , 2007, Current medicinal chemistry.

[15]  K. Marshall,et al.  Identifying leukocyte gene expression patterns associated with plasma lipid levels in human subjects. , 2007, Atherosclerosis.

[16]  N. Ghosh-Choudhury,et al.  Statin-induced Ras Activation Integrates the Phosphatidylinositol 3-Kinase Signal to Akt and MAPK for Bone Morphogenetic Protein-2 Expression in Osteoblast Differentiation* , 2007, Journal of Biological Chemistry.

[17]  B. Yard,et al.  Atorvastatin interferes with activation of human CD4+ T cells via inhibition of small guanosine triphosphatase (GTPase) activity and caspase‐independent apoptosis , 2006, Clinical and experimental immunology.

[18]  W. Stetler-Stevenson,et al.  TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118 , 2006, Oncogene.

[19]  M. Vázquez-Carrera,et al.  Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. , 2006, Biochemical pharmacology.

[20]  Jennifer G. Robinson,et al.  Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. , 2005, Journal of the American College of Cardiology.

[21]  Zhiyong Lin,et al.  Kruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial Cells , 2005, Circulation.

[22]  Ashok Kumar,et al.  Differential Involvement of Calmodulin-dependent Protein Kinase II-activated AP-1 and c-Jun N-terminal Kinase-activated EGR-1 Signaling Pathways in Tumor Necrosis Factor-α and Lipopolysaccharide-induced CD44 Expression in Human Monocytic Cells* , 2005, Journal of Biological Chemistry.

[23]  R. Naoumova,et al.  Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis , 2005, Journal of thrombosis and haemostasis : JTH.

[24]  C. Der,et al.  GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors , 2005, Nature Reviews Molecular Cell Biology.

[25]  W. Stetler-Stevenson,et al.  Tissue Inhibitors of Metalloproteinase 2 Inhibits Endothelial Cell Migration through Increased Expression of RECK , 2004, Cancer Research.

[26]  A. Aljada,et al.  Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. , 2004, The American journal of clinical nutrition.

[27]  Elizabeth S. Gold,et al.  Simvastatin Augments Lipopolysaccharide-Induced Proinflammatory Responses in Macrophages by Differential Regulation of the c-Fos and c-Jun Transcription Factors1 , 2004, The Journal of Immunology.

[28]  R. Jacob,et al.  Effects of HMG-CoA Reductase Inhibitors on Endothelial Function: Role of Microdomains and Oxidative Stress , 2004, Circulation.

[29]  P. Libby,et al.  Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? , 2004, Circulation.

[30]  K. Arnesen,et al.  Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[31]  B. Seetharam,et al.  Transcobalamin II Receptor Interacts with Megalin in the Renal Apical Brush Border Membrane , 2003, The Journal of Membrane Biology.

[32]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[33]  Yoav Benjamini,et al.  Identifying differentially expressed genes using false discovery rate controlling procedures , 2003, Bioinform..

[34]  A. McIntosh,et al.  ACBP and cholesterol differentially alter fatty acyl CoA utilization by microsomal ACAT Published, JLR Papers in Press, October 1, 2002. DOI 10.1194/jlr.M200191-JLR200 , 2003, Journal of Lipid Research.

[35]  R. Valenta,et al.  Cerivastatin and atorvastatin inhibit IL‐3‐dependent differentiation and IgE‐mediated histamine release in human basophils and downmodulate expression of the basophil‐activation antigen CD203c/E‐NPP3 , 2003, Journal of leukocyte biology.

[36]  A. Palazzuoli,et al.  Time‐dependent effect of statins on platelet function in hypercholesterolaemia , 2002, European journal of clinical investigation.

[37]  Joerg Kallen,et al.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.

[38]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[39]  E. Ikonen,et al.  How cells handle cholesterol. , 2000, Science.

[40]  P. Karplus,et al.  Structure of the ERM Protein Moesin Reveals the FERM Domain Fold Masked by an Extended Actin Binding Tail Domain , 2000, Cell.

[41]  J. Gliemann,et al.  Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands. , 1998, Biological chemistry.

[42]  M. Braddock,et al.  Fluid shear stress activation of egr-1 transcription in cultured human endothelial and epithelial cells is mediated via the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway. , 1998, The Journal of clinical investigation.

[43]  M. Bretscher,et al.  Cholesterol and the Golgi apparatus. , 1993, Science.

[44]  J. Denburg,et al.  Interleukin-5 is a human basophilopoietin: induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors. , 1991, Blood.

[45]  F. Field,et al.  Effect of lovastatin on acyl-CoA: cholesterol O-acyltransferase (ACAT) activity and the basolateral-membrane secretion of newly synthesized lipids by CaCo-2 cells. , 1990, The Biochemical journal.

[46]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[47]  琢 波田野.  Leucine-rich repeat kinase 2 associates with lipid rafts , 2007 .

[48]  S. Kumar,et al.  Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. , 1997, Journal of molecular and cellular cardiology.

[49]  A. Catapano,et al.  Pharmacology of competitive inhibitors of HMG-CoA reductase. , 1995, Pharmacological research.